scholarly journals Tyrosine kinase inhibitor and rituximab-CHOP treatment for concurrent chronic myeloid leukemia and non-Hodgkin lymphoma: a case report

2017 ◽  
Vol 5 (12) ◽  
pp. 2047-2050
Author(s):  
Yuki Takeyasu ◽  
Atsushi Satake ◽  
Yoshiko Azuma ◽  
Yukie Tsubokura ◽  
Hideaki Yoshimura ◽  
...  
2016 ◽  
Vol 10 (1) ◽  
Author(s):  
Acy Quixada ◽  
Pedro Aurio Maia Filho ◽  
Tarcísio Paulo Almeida Filho ◽  
Fernando Barroso Duarte ◽  
Caroline Aquino Moreira-Nunes ◽  
...  

2015 ◽  
Vol 16 (7) ◽  
pp. 677-679 ◽  
Author(s):  
Geoffroy Venton ◽  
Julien Colle ◽  
Cedric Mercier ◽  
Raphaelle Fanciullino ◽  
Joseph Ciccolini ◽  
...  

F1000Research ◽  
2022 ◽  
Vol 10 ◽  
pp. 571
Author(s):  
Siprianus Ugroseno Yudho Bintoro ◽  
Pradana Zaky Romadhon ◽  
Satriyo Dwi Suryantoro ◽  
Rusdi Zakki Aminy ◽  
Choirina Windradi ◽  
...  

Priapism in chronic myeloid leukemia (CML) appears to be an infrequent manifestation as well as a crucial emergency. Here, we report an 18-year-old male presenting with a persistent erection of the penis for 20 days. We evaluated and compared the reported cases within 20 years discussing the management of priapism in CML. Cytoreductive therapy followed by leukapheresis, the administration of tyrosine kinase inhibitor, and intra-cavernosal blood aspiration may resolve the symptoms of priapism. Early intervention for cytoreduction and aspiration are the pivotal keys to successfully impeding the complications.


2013 ◽  
Vol 13 (7) ◽  
pp. 755-767 ◽  
Author(s):  
Domenico Russo ◽  
Michele Malagola ◽  
Cristina Skert ◽  
Carla Filì ◽  
Cesare Bergonzi ◽  
...  

2019 ◽  
Vol 4 (1-2) ◽  
pp. 41-45 ◽  
Author(s):  
Takeo Koshida ◽  
Sylvia Wu ◽  
Hitoshi Suzuki ◽  
Rimda Wanchoo ◽  
Vanesa Bijol ◽  
...  

Dasatinib is the second-generation tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia. Proteinuria has been reported with this agent. We describe two kidney biopsy–proven cases of dasatinib-induced thrombotic microangiopathy that responded to stoppage of dasatinib and using an alternate tyrosine kinase inhibitor. Certain specific tyrosine kinase inhibitors lead to endothelial injury and renal-limited thrombotic microangiopathy. Hematologists and nephrologists need to be familiar with this off-target effect of dasatinib.


Sign in / Sign up

Export Citation Format

Share Document